Phase I/II Open-label Randomized Multicenter Trial to Assess Immunogenicity and Safety of 4 Prime-boost Combinations of HIV Vaccine Candidates (MVA HIV-B/ LIPO-5; LIPO-5/MVA HIV-B; GTU®-MultiHIV B / LIPO-5; GTU®-MultiHIV B/MVA HIV-B) in Healthy Volunteers at Low Risk of HIV Infection

Trial Profile

Phase I/II Open-label Randomized Multicenter Trial to Assess Immunogenicity and Safety of 4 Prime-boost Combinations of HIV Vaccine Candidates (MVA HIV-B/ LIPO-5; LIPO-5/MVA HIV-B; GTU®-MultiHIV B / LIPO-5; GTU®-MultiHIV B/MVA HIV-B) in Healthy Volunteers at Low Risk of HIV Infection

Completed
Phase of Trial: Phase I/II

Latest Information Update: 29 Aug 2017

At a glance

  • Drugs Anti-HIV lipopeptide vaccine (Primary) ; HIV DNA vaccine (Primary) ; HIV DNA vaccine (Primary) ; MVA HIV vaccine (Primary)
  • Indications HIV infections
  • Focus Adverse reactions; Therapeutic Use
  • Acronyms ANRS/INSERM VRI01; VRI01
  • Most Recent Events

    • 29 Aug 2017 New trial record
    • 26 Jul 2017 Primary endpoint (Proportion of IFN--ELISPOT responders at Wk30, aiming to discard strategies with 50% responders (M2L2, L2M2, D3L2 group)) has not been met as per the results presented at the 9th International AIDS Society Conference on HIV Science.
    • 26 Jul 2017 Primary endpoint (Proportion of IFN--ELISPOT responders at Wk30, aiming to discard strategies with 50% responders (D3M2 group)) has been met as per the results presented at the 9th International AIDS Society Conference on HIV Science
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top